Dabrowska Magdalena M, Flisiak Robert
Klinika Chorób Zakaźnych i Hepatologii Uniwersytetu Medycznego w Białymstoku.
Przegl Epidemiol. 2010;64(2):319-22.
To asses the yellow fever effectiveness in persons traveling to the endemic regions, and the frequency of adverse events related to vaccine as well as the change of neutralizing antibodies in time.
Fifty three persons (25 males and 28 females, mean 43.5 years) vaccinated against yellow fever in 2004-2008 were involved to the study. In 2009 the level of serum anti-yellow fever antibodies was measured by neutralization test. MAIN OBSERVATION AND RESULTS: None of studied person demonstrated adverse events related to yellow fever vaccine. Four subjects (7.5%) did not respond appropriately to the vaccine. There was no correlation between the level of neutralizing antibodies and gender, age, co-morbidities presence and duration of time after vaccination.
Currently used anti-yellow fever vaccine demonstrates high level of efficacy and safety. Above 92% of studied persons had protective level of neutralizing antibodies. Moreover, the postvaccinal response seems to be long-term and does not depend on time period from vaccination or other factors.
评估前往黄热病流行地区的人群中黄热病疫苗的有效性、与疫苗相关的不良事件发生频率以及中和抗体随时间的变化情况。
本研究纳入了2004年至2008年期间接种黄热病疫苗的53人（25名男性和28名女性，平均年龄43.5岁）。2009年通过中和试验检测血清抗黄热病抗体水平。主要观察指标与结果：所有研究对象均未出现与黄热病疫苗相关的不良事件。4名受试者（7.5%）对疫苗无适当反应。中和抗体水平与性别、年龄、合并症情况及接种后时间长短无关。
目前使用的黄热病疫苗显示出高度的有效性和安全性。超过92%的研究对象具有中和抗体的保护水平。此外，疫苗接种后的反应似乎是长期的，且不依赖于接种后的时间段或其他因素。
